GENESIS Pharma engages in the sales and marketing of a unique portfolio of branded biopharmaceutical products principally within the specialty therapeutic areas of Oncology, Hematology, Nephrology and the Central Nervous System (CNS).

Many of these products treat rare chronic or life-threatening diseases and most of them address previously unmet or underserved clinical needs.

Products marketed and sold by GENESIS Pharma are:

ABRAXANE (nanoparticle albumin bound paclitaxel)
Celgene Europe Ltd

AVONEX^® (Interferon Beta-1a)
Biogen Idec Ltd

FERINJECT (Intravenous Iron Carboxymaltose)
Vifor France SA

FOSRENOL^® (Lanthanum carbonate)
Shire Pharmaceutical Contracts Ltd

GLIADEL^® Wafer (Polifeprosan 20 with carmustine implant)
Eisai Inc

KINERET^® (Anakinra)
Swedish Orphan Biovitrum AB

MEPACT (Mifamurtide)
Takeda Pharmaceutical Europe Ltd

MEZAVANT (Mesalazine)
Shire Pharmaceutical Contracts Ltd

MODIODAL^® (Modafinil)
Cephalon Europe

MYOCET (Doxorubicin HCl)
Cephalon Europe

RESOLOR^® (Prucalopride)
Shire-Movetis N.V.

REVLIMID^® (Lenalidomide)
Celgene Europe Ltd

THALIDOMIDE CELGENE^® (Thalidomide)
Celgene Europe Ltd

TYSABRI^® (Natalizumab)
Biogen Idec Ltd- Elan Pharma International Ltd

VENOFER^® (IV Iron)
Vifor France SA

VIDAZA (Azacitidine)
Celgene Europe Ltd

XAGRID^® (Anagrelide Hydrochloride)
Shire Pharmaceutical Contracts Ltd

YONDELIS^® (Trabectedin)
PharmaMar SA